secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptevo Therapeutics Inc. (APVO)
CIK:        0001671584
Form:       8-K
Filed at:   2026-08-14T12:10:17+00:00
Accession:  0001193125-26-350537
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptevo Q2: mipletamig 81% remission in AML; Niowave 50/50 radiopharma deal
--------------------------------------------------------------------------

- Cash $9.8M at June 30, 2026; raised $0.6M under Yorkville SEPAs in Q2.
- Mipletamig: 87% clinical benefit rate, 81% remission rate in 31 frontline AML patients; 55% MRD neg, 36% TP53, 6 bridged to transplant.
- Appointed Mary J. Janatpour, Ph.D. as SVP and Chief Scientific Officer.
- Secured $1.5M non-dilutive grant from Andy Hill CARE Fund for APVO451 IND-enabling work; candidate selection by year-end 2026.
- Entered 50/50 collaboration with Niowave for up to three radiopharmaceutical programs; Niowave took 7.9% equity stake (up to 19.99%).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671584/000119312526350537/0001193125-26-350537-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671584/000119312526350537/apvo-20260814.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-350537

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer